Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.430
-0.110 (-4.33%)
At close: Aug 28, 2026, 4:00 PM EDT
2.430
-0.001 (-0.02%)
After-hours: Aug 28, 2026, 7:48 PM EDT

Fate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6.496.6513.6363.5396.355.85
Revenue Growth
-23.36%-51.24%-78.55%-34.03%72.44%77.66%
Cost of Revenue
84.4291.9118.53157.19320.45215.52
Gross Profit
-77.93-85.25-104.9-93.65-224.15-159.67
Selling, General & Admin
54.5661.3590.6496.8684.2357.32
Operating Expenses
54.5661.3590.6496.8684.2357.32
Operating Income
-132.49-146.6-195.54-190.51-308.39-216.99
Interest & Investment Income
8.2211.0517.2917.195.841.31
Other Non Operating Income (Expenses)
-0.620.346.737.320.323.53
EBT Excluding Unusual Items
-124.9-135.22-171.53-166.03-282.22-212.15
Merger & Restructuring Charges
-1.1-1.1----
Asset Writedown
---14.74---
Other Unusual Items
---5.10.5-
Pretax Income
-126-136.32-186.26-160.93-281.72-212.15
Net Income
-126-136.32-186.26-160.93-281.72-212.15
Net Income to Common
-126-136.32-186.26-160.93-281.72-212.15
Net Income Growth
------
Shares Outstanding (Basic)
120119114989795
Shares Outstanding (Diluted)
120119114989795
Shares Change
1.19%4.49%15.52%1.64%2.19%15.00%
EPS (Basic)
-1.05-1.15-1.64-1.64-2.91-2.24
EPS (Diluted)
-1.05-1.15-1.64-1.64-2.91-2.24
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-105.66-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Per Share
-0.88-0.94-1.09-1.41-2.93-2.25
Gross Margin
----147.41%-232.77%-285.92%
Operating Margin
-2041.13%-2205.90%-1434.52%-299.86%-320.24%-388.56%
Profit Margin
-1941.09%-2051.08%-1366.46%-253.30%-292.55%-379.89%
Free Cash Flow Margin
-1627.76%-1685.78%-906.79%-217.87%-294.68%-382.43%
EBITDA
-120.5-133.7-176.58-172.23-294.63-211.14
EBITDA Margin
----271.09%--
D&A For EBITDA
11.9912.918.9618.2813.765.85
EBIT
-132.49-146.6-195.54-190.51-308.39-216.99
EBIT Margin
----299.86%--
SEC Filings: 10-K · 10-Q